UA73501C2 - b-ARYL-a-OXYSUBSTITUTED ALKYLCARBOXYLIC ACIDS, A METHOD FOR THE PREPARATION THEREOF (VARIANTS), PHARMACEUTICAL COMPOSITION BASED THEREON (VARIANTS), METHODS FOR PREVENTION AND TREATMENT WITH USE THEREOF, INTERMEDIARY COMPOUNDS AND A METHOD FOR THE PREPARATION THEREOF (VARIANTS) - Google Patents
b-ARYL-a-OXYSUBSTITUTED ALKYLCARBOXYLIC ACIDS, A METHOD FOR THE PREPARATION THEREOF (VARIANTS), PHARMACEUTICAL COMPOSITION BASED THEREON (VARIANTS), METHODS FOR PREVENTION AND TREATMENT WITH USE THEREOF, INTERMEDIARY COMPOUNDS AND A METHOD FOR THE PREPARATION THEREOF (VARIANTS) Download PDFInfo
- Publication number
- UA73501C2 UA73501C2 UA2001118039A UA2001118039A UA73501C2 UA 73501 C2 UA73501 C2 UA 73501C2 UA 2001118039 A UA2001118039 A UA 2001118039A UA 2001118039 A UA2001118039 A UA 2001118039A UA 73501 C2 UA73501 C2 UA 73501C2
- Authority
- UA
- Ukraine
- Prior art keywords
- dihydro
- ethoxy
- phenyl
- acid
- benzoxazin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 46
- 239000002253 acid Substances 0.000 title claims abstract 24
- 150000007513 acids Chemical class 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 title claims 8
- 230000002265 prevention Effects 0.000 title claims 6
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 135
- 239000012453 solvate Substances 0.000 claims abstract 13
- 208000008589 Obesity Diseases 0.000 claims abstract 4
- 235000020824 obesity Nutrition 0.000 claims abstract 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 190
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 183
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 163
- -1 2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy Chemical group 0.000 claims 124
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 122
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 122
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 122
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 119
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 118
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 118
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 118
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims 118
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 118
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims 118
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 116
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 116
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 116
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 116
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 90
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 62
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 62
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 61
- 239000004475 Arginine Substances 0.000 claims 61
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 61
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 61
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 61
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 61
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 61
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 61
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 61
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 61
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 61
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 61
- 239000004472 Lysine Substances 0.000 claims 61
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 61
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 61
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 61
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 61
- 239000004473 Threonine Substances 0.000 claims 61
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 61
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 61
- 235000018417 cysteine Nutrition 0.000 claims 61
- 229960003067 cystine Drugs 0.000 claims 61
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 61
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 61
- 229960003194 meglumine Drugs 0.000 claims 61
- 229930182817 methionine Natural products 0.000 claims 61
- 229960003104 ornithine Drugs 0.000 claims 61
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 61
- 235000008729 phenylalanine Nutrition 0.000 claims 61
- 229960005190 phenylalanine Drugs 0.000 claims 61
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 61
- 229960004919 procaine Drugs 0.000 claims 61
- 150000003212 purines Chemical class 0.000 claims 61
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 claims 61
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 61
- 229960000281 trometamol Drugs 0.000 claims 61
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 60
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 60
- 229910052782 aluminium Chemical class 0.000 claims 60
- 150000003863 ammonium salts Chemical class 0.000 claims 60
- 229940043237 diethanolamine Drugs 0.000 claims 60
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 60
- 229960000310 isoleucine Drugs 0.000 claims 60
- 229960004559 theobromine Drugs 0.000 claims 60
- UKHBJYFFALMACQ-UHFFFAOYSA-N 2-(3-benzylphenyl)ethanamine Chemical compound NCCC1=CC=CC(CC=2C=CC=CC=2)=C1 UKHBJYFFALMACQ-UHFFFAOYSA-N 0.000 claims 59
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 59
- MWGATWIBSKHFMR-UHFFFAOYSA-N 2-anilinoethanol Chemical compound OCCNC1=CC=CC=C1 MWGATWIBSKHFMR-UHFFFAOYSA-N 0.000 claims 59
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims 59
- 239000004471 Glycine Substances 0.000 claims 59
- QMXOFBXZEKTJIK-UHFFFAOYSA-N Glycinol Natural products C1=C(O)C=C2OCC3(O)C4=CC=C(O)C=C4OC3C2=C1 QMXOFBXZEKTJIK-UHFFFAOYSA-N 0.000 claims 59
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 59
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 59
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 59
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 59
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 claims 59
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 59
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 59
- 150000003927 aminopyridines Chemical class 0.000 claims 59
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 59
- 229960001231 choline Drugs 0.000 claims 59
- 125000005265 dialkylamine group Chemical group 0.000 claims 59
- 229940063673 spermidine Drugs 0.000 claims 59
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims 59
- 235000019157 thiamine Nutrition 0.000 claims 59
- 229960003495 thiamine Drugs 0.000 claims 59
- 239000011721 thiamine Substances 0.000 claims 59
- 125000005270 trialkylamine group Chemical group 0.000 claims 59
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 59
- 239000004474 valine Substances 0.000 claims 59
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 58
- 229940013085 2-diethylaminoethanol Drugs 0.000 claims 58
- JBQWQBSRIAGTJT-UHFFFAOYSA-N 3-ethylmorpholine Chemical compound CCC1COCCN1 JBQWQBSRIAGTJT-UHFFFAOYSA-N 0.000 claims 58
- YLUDSYGJHAQGOD-UHFFFAOYSA-N 3-ethylpiperidine Chemical compound CCC1CCCNC1 YLUDSYGJHAQGOD-UHFFFAOYSA-N 0.000 claims 58
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 58
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 58
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims 58
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 58
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 58
- 229960003237 betaine Drugs 0.000 claims 58
- 229960001948 caffeine Drugs 0.000 claims 58
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 58
- 229960002442 glucosamine Drugs 0.000 claims 58
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims 58
- 235000004279 alanine Nutrition 0.000 claims 57
- 229940075419 choline hydroxide Drugs 0.000 claims 57
- 229960002591 hydroxyproline Drugs 0.000 claims 57
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 56
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 56
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 56
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims 55
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 55
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 54
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 claims 54
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 claims 53
- 150000005005 aminopyrimidines Chemical class 0.000 claims 53
- 229940012017 ethylenediamine Drugs 0.000 claims 46
- 150000002357 guanidines Chemical class 0.000 claims 42
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 36
- 125000000217 alkyl group Chemical group 0.000 claims 31
- 229910052739 hydrogen Inorganic materials 0.000 claims 30
- 239000001257 hydrogen Substances 0.000 claims 30
- 150000002431 hydrogen Chemical class 0.000 claims 17
- 201000010099 disease Diseases 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 208000011580 syndromic disease Diseases 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 13
- 229910052760 oxygen Inorganic materials 0.000 claims 13
- 239000001301 oxygen Substances 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 150000001721 carbon Chemical group 0.000 claims 12
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 208000017169 kidney disease Diseases 0.000 claims 11
- 125000001624 naphthyl group Chemical group 0.000 claims 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 11
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 10
- 206010020772 Hypertension Diseases 0.000 claims 9
- 206010022489 Insulin Resistance Diseases 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 238000006243 chemical reaction Methods 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 206010003210 Arteriosclerosis Diseases 0.000 claims 6
- 208000032928 Dyslipidaemia Diseases 0.000 claims 6
- 206010018364 Glomerulonephritis Diseases 0.000 claims 6
- 208000002705 Glucose Intolerance Diseases 0.000 claims 6
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 6
- 102000016267 Leptin Human genes 0.000 claims 6
- 108010092277 Leptin Proteins 0.000 claims 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 6
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 6
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 6
- 208000001132 Osteoporosis Diseases 0.000 claims 6
- 206010033645 Pancreatitis Diseases 0.000 claims 6
- 201000004681 Psoriasis Diseases 0.000 claims 6
- 208000017442 Retinal disease Diseases 0.000 claims 6
- 206010038923 Retinopathy Diseases 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- 206010048215 Xanthomatosis Diseases 0.000 claims 6
- 230000004913 activation Effects 0.000 claims 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims 6
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 6
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 6
- 206010009887 colitis Diseases 0.000 claims 6
- 206010061989 glomerulosclerosis Diseases 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 230000001631 hypertensive effect Effects 0.000 claims 6
- 230000002757 inflammatory effect Effects 0.000 claims 6
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 6
- 229940039781 leptin Drugs 0.000 claims 6
- 125000004957 naphthylene group Chemical group 0.000 claims 6
- 201000009925 nephrosclerosis Diseases 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 239000011593 sulfur Chemical group 0.000 claims 6
- MWAGUKZCDDRDCS-UHFFFAOYSA-N 1-nitro-4-(4-nitrophenoxy)benzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C([N+]([O-])=O)C=C1 MWAGUKZCDDRDCS-UHFFFAOYSA-N 0.000 claims 5
- 229920001268 Cholestyramine Polymers 0.000 claims 5
- 229920002911 Colestipol Polymers 0.000 claims 5
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims 5
- 229960002604 colestipol Drugs 0.000 claims 5
- 210000002889 endothelial cell Anatomy 0.000 claims 5
- 229940125753 fibrate Drugs 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 229960003512 nicotinic acid Drugs 0.000 claims 5
- 235000001968 nicotinic acid Nutrition 0.000 claims 5
- 239000011664 nicotinic acid Substances 0.000 claims 5
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims 5
- 229960003912 probucol Drugs 0.000 claims 5
- 230000002195 synergetic effect Effects 0.000 claims 5
- 108010028554 LDL Cholesterol Proteins 0.000 claims 4
- 206010048214 Xanthoma Diseases 0.000 claims 4
- 229940118148 Aldose reductase inhibitor Drugs 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000003288 aldose reductase inhibitor Substances 0.000 claims 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000003920 cognitive function Effects 0.000 claims 3
- 208000029078 coronary artery disease Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 235000021588 free fatty acids Nutrition 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 210000002381 plasma Anatomy 0.000 claims 3
- 150000003626 triacylglycerols Chemical class 0.000 claims 3
- XBHQOMRKOUANQQ-UHFFFAOYSA-N 2-ethoxypropanoic acid Chemical compound CCOC(C)C(O)=O XBHQOMRKOUANQQ-UHFFFAOYSA-N 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 101100202882 Homo sapiens SELENOO gene Proteins 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims 2
- 102100022022 Protein adenylyltransferase SelO, mitochondrial Human genes 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 239000008096 xylene Substances 0.000 claims 2
- FGMPLJWBKKVCDB-BYPYZUCNSA-N (2s)-1-hydroxypyrrolidine-2-carboxylic acid Chemical compound ON1CCC[C@H]1C(O)=O FGMPLJWBKKVCDB-BYPYZUCNSA-N 0.000 claims 1
- QCZKLKFGDITLCF-UHFFFAOYSA-N 2-ethoxyprop-2-enoic acid Chemical compound CCOC(=C)C(O)=O QCZKLKFGDITLCF-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241001331845 Equus asinus x caballus Species 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- 241000755093 Gaidropsarus vulgaris Species 0.000 claims 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 210000004894 snout Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN484MA1999 | 1999-04-28 | ||
PCT/IB2000/000501 WO2000066572A1 (en) | 1999-04-28 | 2000-04-25 | Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
UA73501C2 true UA73501C2 (en) | 2005-08-15 |
Family
ID=11095336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2001118039A UA73501C2 (en) | 1999-04-28 | 2000-04-25 | b-ARYL-a-OXYSUBSTITUTED ALKYLCARBOXYLIC ACIDS, A METHOD FOR THE PREPARATION THEREOF (VARIANTS), PHARMACEUTICAL COMPOSITION BASED THEREON (VARIANTS), METHODS FOR PREVENTION AND TREATMENT WITH USE THEREOF, INTERMEDIARY COMPOUNDS AND A METHOD FOR THE PREPARATION THEREOF (VARIANTS) |
Country Status (25)
Country | Link |
---|---|
US (1) | US7348426B1 (no) |
EP (1) | EP1175412A1 (no) |
JP (1) | JP2002543194A (no) |
KR (1) | KR100610578B1 (no) |
CN (1) | CN1353699A (no) |
AU (1) | AU781079B2 (no) |
BG (1) | BG106146A (no) |
BR (1) | BR0010139A (no) |
CA (1) | CA2371757A1 (no) |
CZ (1) | CZ20013832A3 (no) |
EE (1) | EE200100540A (no) |
HR (1) | HRP20010785A2 (no) |
HU (1) | HUP0600105A3 (no) |
IL (1) | IL146104A0 (no) |
MX (1) | MXPA01010916A (no) |
NO (1) | NO320805B1 (no) |
NZ (1) | NZ515284A (no) |
PL (1) | PL351987A1 (no) |
RU (1) | RU2278114C2 (no) |
SK (1) | SK15092001A3 (no) |
TR (1) | TR200103848T2 (no) |
UA (1) | UA73501C2 (no) |
WO (1) | WO2000066572A1 (no) |
YU (1) | YU75101A (no) |
ZA (1) | ZA200108733B (no) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002030914A1 (en) * | 2000-10-12 | 2002-04-18 | Dr. Reddy's Research Foundation | Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them |
CA2458621A1 (en) * | 2001-08-29 | 2003-03-06 | Warner-Lambert Company Llc | Oral antidiabetic agents |
WO2003024944A1 (en) * | 2001-09-20 | 2003-03-27 | Dr. Reddy's Laboratories Ltd. | An improved process for the preparation of bicyclic antidiabetic compounds |
WO2003027084A1 (en) * | 2001-09-25 | 2003-04-03 | Dr. Reddy's Laboratories Ltd. | Improved process for the preparation of optically active phenoxazine derivatives as antidiabetic agents |
WO2003033456A1 (en) * | 2001-10-16 | 2003-04-24 | Dr. Reddy's Laboratories Ltd. | NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS |
AU2003244514A1 (en) * | 2002-02-07 | 2003-09-02 | Dr. Reddy's Laboratories Limited | Novel polymorphic forms of bicyclic antidiabetic agents: process for their preparation and pharmaceutical compositions containing them |
US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
AU2003232472B2 (en) | 2002-04-30 | 2008-09-18 | Ucb Pharma | 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors |
WO2003099800A1 (en) * | 2002-05-23 | 2003-12-04 | Dr. Reddy's Laboratories Limited | An improved process for the preparation of bicyclic antidiabetic agents |
ATE377419T1 (de) | 2002-11-08 | 2007-11-15 | Hoffmann La Roche | Substituierte 4-alkoxyoxazol derivate als ppar agonisten |
US7262303B2 (en) * | 2003-09-29 | 2007-08-28 | Hoffman-La Roche Inc. | Process for the production of chiral propionic acid derivatives |
DE202004002953U1 (de) * | 2004-02-26 | 2004-04-29 | Winkler, Wilhelm | Verbindungseinheit |
US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
AU2006254772B2 (en) | 2005-06-09 | 2011-06-02 | Ucb Pharma S.A. | 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament |
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
RU2684779C2 (ru) * | 2016-02-05 | 2019-04-15 | АО "Институт химических наук им. А.Б. Бектурова" | Применение производного бета-морфолинопропиоамидоксима в качестве противодиабетического средства |
CN110092774B (zh) * | 2018-01-29 | 2022-04-08 | 中国科学院上海药物研究所 | 芳香丙酸类衍生物、及其制备方法和用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK173350B1 (da) * | 1985-02-26 | 2000-08-07 | Sankyo Co | Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem |
GB9027023D0 (en) * | 1990-12-12 | 1991-01-30 | Wellcome Found | Anti-atherosclerotic aryl compounds |
GB9225386D0 (en) | 1992-12-04 | 1993-01-27 | Smithkline Beecham Plc | Novel compounds |
BR9508468A (pt) | 1994-07-29 | 1997-11-25 | Smithkline Beecham Plc | Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário |
JPH0912575A (ja) * | 1995-06-28 | 1997-01-14 | Sankyo Co Ltd | ベンゾオキサジンおよびベンゾチアジン誘導体 |
GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
WO1997028149A1 (en) * | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
GB9606805D0 (en) * | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
WO1998002159A1 (en) | 1996-07-12 | 1998-01-22 | Smithkline Beecham Plc | Novel treatment of leptine resistance |
AU752059B2 (en) * | 1997-10-27 | 2002-09-05 | Dr. Reddy's Laboratories Limited | Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
US6265401B1 (en) * | 1997-10-27 | 2001-07-24 | Reddy-Cheminor, Inc. | Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
EP1082313A1 (en) * | 1998-05-27 | 2001-03-14 | Dr. Reddy's Research Foundation | Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
-
2000
- 2000-04-25 WO PCT/IB2000/000501 patent/WO2000066572A1/en not_active Application Discontinuation
- 2000-04-25 AU AU39831/00A patent/AU781079B2/en not_active Ceased
- 2000-04-25 EE EEP200100540A patent/EE200100540A/xx unknown
- 2000-04-25 NZ NZ515284A patent/NZ515284A/xx unknown
- 2000-04-25 JP JP2000615602A patent/JP2002543194A/ja not_active Withdrawn
- 2000-04-25 PL PL00351987A patent/PL351987A1/xx not_active Application Discontinuation
- 2000-04-25 SK SK1509-2001A patent/SK15092001A3/sk unknown
- 2000-04-25 HU HU0600105A patent/HUP0600105A3/hu unknown
- 2000-04-25 CA CA002371757A patent/CA2371757A1/en not_active Abandoned
- 2000-04-25 EP EP00919081A patent/EP1175412A1/en not_active Withdrawn
- 2000-04-25 CZ CZ20013832A patent/CZ20013832A3/cs unknown
- 2000-04-25 IL IL14610400A patent/IL146104A0/xx unknown
- 2000-04-25 MX MXPA01010916A patent/MXPA01010916A/es active IP Right Grant
- 2000-04-25 KR KR1020017013604A patent/KR100610578B1/ko not_active IP Right Cessation
- 2000-04-25 YU YU75101A patent/YU75101A/sh unknown
- 2000-04-25 TR TR2001/03848T patent/TR200103848T2/xx unknown
- 2000-04-25 UA UA2001118039A patent/UA73501C2/uk unknown
- 2000-04-25 CN CN00808424A patent/CN1353699A/zh active Pending
- 2000-04-25 RU RU2001132085/04A patent/RU2278114C2/ru not_active IP Right Cessation
- 2000-04-25 BR BR0010139-7A patent/BR0010139A/pt not_active IP Right Cessation
- 2000-04-25 US US09/959,093 patent/US7348426B1/en not_active Expired - Fee Related
-
2001
- 2001-10-23 ZA ZA200108733A patent/ZA200108733B/en unknown
- 2001-10-24 HR HR20010785A patent/HRP20010785A2/hr not_active Application Discontinuation
- 2001-10-26 NO NO20015259A patent/NO320805B1/no unknown
- 2001-11-26 BG BG106146A patent/BG106146A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
YU75101A (sh) | 2005-07-19 |
BG106146A (bg) | 2002-05-31 |
US7348426B1 (en) | 2008-03-25 |
AU781079B2 (en) | 2005-05-05 |
NO320805B1 (no) | 2006-01-30 |
JP2002543194A (ja) | 2002-12-17 |
NO20015259L (no) | 2001-11-15 |
NZ515284A (en) | 2004-12-24 |
NO20015259D0 (no) | 2001-10-26 |
CN1353699A (zh) | 2002-06-12 |
SK15092001A3 (sk) | 2002-05-09 |
IL146104A0 (en) | 2002-07-25 |
ZA200108733B (en) | 2003-01-23 |
KR20010113891A (ko) | 2001-12-28 |
HRP20010785A2 (en) | 2003-02-28 |
KR100610578B1 (ko) | 2006-08-09 |
CA2371757A1 (en) | 2000-11-09 |
CZ20013832A3 (cs) | 2002-04-17 |
RU2278114C2 (ru) | 2006-06-20 |
HUP0600105A2 (en) | 2006-05-29 |
EP1175412A1 (en) | 2002-01-30 |
TR200103848T2 (tr) | 2002-04-22 |
AU3983100A (en) | 2000-11-17 |
BR0010139A (pt) | 2004-03-02 |
MXPA01010916A (es) | 2002-06-21 |
WO2000066572A1 (en) | 2000-11-09 |
HUP0600105A3 (en) | 2006-11-28 |
EE200100540A (et) | 2002-12-16 |
PL351987A1 (en) | 2003-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA73501C2 (en) | b-ARYL-a-OXYSUBSTITUTED ALKYLCARBOXYLIC ACIDS, A METHOD FOR THE PREPARATION THEREOF (VARIANTS), PHARMACEUTICAL COMPOSITION BASED THEREON (VARIANTS), METHODS FOR PREVENTION AND TREATMENT WITH USE THEREOF, INTERMEDIARY COMPOUNDS AND A METHOD FOR THE PREPARATION THEREOF (VARIANTS) | |
CN100357281C (zh) | 双环化合物、其制备方法和包含它们的药物组合物 | |
CN1352639A (zh) | 新的三环化合物及其在医药中的应用,它们的制备方法和含有它们的药物组合物 | |
US20010027198A1 (en) | Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | |
EA008947B1 (ru) | АГОНИСТЫ PPARα И ИХ ПРИМЕНЕНИЕ | |
Sadashiva et al. | Synthesis and efficacy of 1-[bis (4-fluorophenyl)-methyl] piperazine derivatives for acetylcholinesterase inhibition, as a stimulant of central cholinergic neurotransmission in Alzheimer’s disease | |
JP2004534733A (ja) | 血中コレステロール低下剤剤としてのアリール置換アルキルカルボン酸 | |
CA2748066C (en) | Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | |
CN109651208B (zh) | N-芳基磺酰胺类化合物,其药物组合物及其用途 | |
KR102420210B1 (ko) | 치환된 바이사이클릭 디하이드로피리미디논 및 호중구 엘라스타제 활성 억제제로서의 이의 용도 | |
US6265401B1 (en) | Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | |
RU2247722C2 (ru) | Производные арилкарбоновых кислот, способы их получения, фармацевтическая композиция на их основе, способы лечения и предупреждения различных заболеваний, промежуточные соединения и способы их получения | |
JPH05194236A (ja) | 中枢性カルシウム拮抗剤 | |
TW406078B (en) | Novel heterocyclic compounds, the method for the preparation thereof and the pharmaceutical compositions containing the said compounds | |
JPH09278737A (ja) | フェノール誘導体及びその製法 | |
WO1994024117A1 (en) | Benzofurancarboxylic acid derivative and pharmaceutical composition | |
UA73917C2 (en) | Novel tricyclic compounds and use thereof in the medicine; a method for the preparation thereof and pharmaceutical compositions containing such compounds | |
EP1757592A1 (en) | Novel 3-phenyltetrahydrocinnolin-5-ol derivative and medicinal use thereof | |
CZ20001540A3 (cs) | Bicyklické sloučeniny, způsob jejich přípravy a farmaceutické kompozice s jejich obsahem | |
JPH07267939A (ja) | 光学活性な4,1−ベンゾオキサゼピン誘導体とその用途 | |
UA78522C2 (en) | Benzoxasine and benzothiasine derivatives, method for synthesis thereof and pharmaceutical composition (variants) | |
AU2006225184A1 (en) | Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them |